Press release
2025 Antisense & RNAi Therapeutics Industry Trends Report: Long-Term Outlook Through 2034
Antisense & RNAi Therapeutics
How Large Will the Antisense & RNAi Therapeutics Market Size By 2025?
There has been a swift expansion in the antisense & RNAi therapeutics market in the past few years. The market value, which was $1.75 billion in 2024, is predicted to escalate to $1.94 billion in 2025, presenting an impressive compound annual growth rate (CAGR) of 11.2%. The substantial growth witnessed in the historic time frame can be credited to the surge in funding, technological advancements, increase in healthcare spending, acceleration in the growth of the elderly populace, and upward economic trends in growing markets.
How Big Is the Antisense & RNAi Therapeutics Market Size Expected to Grow by 2029?
In the coming years, the antisense & RNAi therapeutics market is projected to experience swift expansion, reaching $3.18 billion by 2029 with a compound annual growth rate (CAGR) of 13.1%. The predicted growth during the forecast period can be ascribed to improved access to healthcare, increasing cancer prevalence, and the rising demand for antisense and RNAi therapeutics due to the COVID-19 pandemic. The forecast period also sees major trends such as concentrated efforts on research and development of RNA therapeutics for rare diseases, utilization of nanoparticles, and the development of enhanced antisense and RNAi therapeutics. Collaborations with other firms for product innovation and revenue generation will also be a key trend.
View the full report here:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report
Which Key Market Drivers Powering Antisense & RNAi Therapeutics Market Expansion and Growth?
The antisense & RNAi therapeutics market is expected to see increased demand due to a surge in the incidence of coronary artery diseases, neurodegenerative illnesses, and infectious ailments. Gene silencing techniques, such as RNA interference and antisense oligonucleotides, are employed to fix mutant genes and manage a variety of neurodegenerative conditions. As an illustration, a report from the American Heart Association, a renowned US organization, indicated that as of January 2024, the age-adjusted death rate from cardiovascular diseases spiked to 233.3 per 100,000, marking a 4.0% increase from the preceding year. Consequently, the rise in the occurrence of various neurodegenerative and infectious diseases is anticipated to fuel the expansion of the antisense & RNAi therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Antisense & RNAi Therapeutics Market?
Key players in the antisense & RNAi therapeutics market are employing strategic moves such as forming collaborations and partnerships to keep their footing in a progressively competitive environment. This strategic cooperation is a business tactic that sees multiple businesses collaborate to reach a shared purpose or aim. For instance, in January 2023, US-based Orbit Discovery Limited, a firm that provides services for the discovery of peptides, established a partnership with SanegeneBio Inc., a UK-based firm known for developing unique RNAi-based medicines. The aim of this partnership is to identify tissue-specific distributions of therapeutics for efficient gene knockdown, as well as to cultivate a collection of enhanced RNAi therapeutics. The partnership will include hit identification and cell-based internalization studies, and SanegeneBio will have the choice to further develop hits that derive from the screening actions. These developments will utilize Orbit's exclusive technology for swift peptide lead discovery. The distinctive peptide display engine of Orbit Discovery facilitates the examination of large peptide libraries, thus providing quicker detection times for appropriate peptide leads relying on affinity and functional screens.
What Are the Emerging Segments in the Antisense & RNAi Therapeutics Market?
The antisense & RNAi therapeutics market covered in this report is segmented -
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp
Who Are the Global Leaders in the Antisense & RNAi Therapeutics Market?
Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical
Which are the Top Profitable Regional Markets for the Antisense & RNAi Therapeutics Industry?
North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2025 Antisense & RNAi Therapeutics Industry Trends Report: Long-Term Outlook Through 2034 here
News-ID: 4102985 • Views: …
More Releases from The Business Research Company
Soaring Demand Set to Propel Architectural, Engineering Consultants And Related …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Architectural, Engineering Consultants And Related Services Market Size By 2025?
In recent times, the market size of architectural, engineering consultants and associated services has seen consistent growth. It is projected to increase from $1489.87 billion in 2024 to $1549.81 billion in 2025, with a compound…
2025-2034 Anesthesia And Respiratory Devices Market Roadmap: Insights for Compet …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Anesthesia And Respiratory Devices Market Size By 2025?
In recent years, there has been a swift expansion in the market size of anesthesia and respiratory devices. The market, which is pegged at $33.63 billion in 2024, is projected to reach $38.29 billion in 2025, marking…
Transformative Trends Impacting the Ambulatory IV infusion Pumps Market Landscap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Ambulatory IV infusion Pumps Market Size By 2025?
In recent times, there has been a consistent increase in the size of the ambulatory IV infusion pumps market. This market, valued at $0.86 billion in 2024, is projected to grow to $0.89 billion in 2025, reflecting…
Environmental Awareness Driving Growth In ATV And UTV Market Driving Market Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the All-Terrain Vehicle (ATV) and Utility Task Vehicle (UTV) Market Size By 2025?
The market for all-terrain vehicles (ATV) and utility task vehicles (UTV) has experienced robust growth in the past few years. The market size, projected to climb from $10.25 billion in 2024 to $11.13…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
